Results 101 to 110 of about 1,993 (117)

Evaluation of SSTR2 Expression in SI-NETs and Relation to Overall Survival after PRRT

Cancers, 2021
(1) Purpose: Small intestinal neuroendocrine tumors (SI-NETs) often present with distant metastases at diagnosis. Peptide receptor radionuclide therapy (PRRT) with radiolabeled somatostatin analogues is a systemic treatment that increases overall ...
Anna-Karin Elf, Anders Bergstrom, Erik Elias   +2 more
exaly   +2 more sources

Prognostic Value of the Largest Lesion Size for Progression-Free Survival in Patients with NET Undergoing Salvage PRRT with [177Lu]Lu-DOTATOC [PDF]

Cancers, 2022
(1) Background: retreatment with radionuclide-labeled somatostatin analogues following disease progression after initial treatment cycles is often referred to as salvage peptide receptor radionuclide therapy (salvage PRRT).
Julian Rogasch, Christoph Wetz, Kai Huang   +2 more
exaly   +3 more sources

PRRT plus holmium‐166‐SIRT (HEPAR PLuS) versus PRRT‐only in patients with metastatic neuroendocrine tumors: A propensity‐score matched analysis

Journal of Neuroendocrinology
Patients with bulky neuroendocrine liver metastases (NELM) undergoing PRRT with [177Lu]Lu-DOTATATE have a worse survival than patients with limited liver metastases. Previously, the safety and efficacy of additional selective internal radiotherapy (SIRT),
Thomas Pierre Walter, Arthur Braat
exaly   +3 more sources

PRRT genomic signature in blood for prediction of 177Lu-octreotate efficacy

European Journal of Nuclear Medicine and Molecular Imaging, 2018
Background: Peptide receptor radionuclide therapy (PRRT) utilizes somatostatin receptor (SSR) overexpression on neuroendocrine tumors (NET) to deliver targeted radiotherapy.
Guido Krenning, Lisa Bodei, Giovanni Paganelli   +2 more
exaly   +2 more sources

Assessment of response to PRRT including anatomical and molecular imaging as well as novel biomarkers [PDF]

Journal of Neuroendocrinology
Peptide receptor radionuclide therapy (PRRT) is an effective treatment for both oncological and hormone control and is a widely accepted standard of care treatment for patients with neuroendocrine neoplasms (NEN).
Grace Kong
exaly   +3 more sources

Some of the next articles are maybe not open access.

Related searches:

Interaction and Subcellular Association of PRRT1/SynDIG4 With AMPA Receptors

Frontiers in Synaptic Neuroscience, 2021
Mohiuddin Ahmad
exaly  

Efficacy and tolerability of peptide receptor radionuclide therapy (PRRT) in advanced metastatic bronchial neuroendocrine tumours (NETs)

Lung Cancer, 2020
Christos Toumpanakis, Eitan Mirvis, Dalvinder Mandair   +2 more
exaly  

Peptide receptor radionuclide therapy (PRRT) for GEP-NETs

Bailliere's Best Practice and Research in Clinical Gastroenterology, 2012
Guido Krenning, Robin Peeters, Wouter de Herder   +2 more
exaly  

Long-term tolerability of PRRT in 807 patients with neuroendocrine tumours: the value and limitations of clinical factors

European Journal of Nuclear Medicine and Molecular Imaging, 2014
Guido Krenning, Lisa Bodei, Mark Kidd
exaly  

The evolution of PRRT for the treatment of neuroendocrine tumors; What comes next?

Frontiers in Endocrinology, 2022
exaly